Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., supplies PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent for positron emission tomography scans, to the Department of Veterans Affairs and other federal healthcare providers as a prime contractor under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The company is a wholly owned subsidiary of Lantheus Holdings, Inc., headquartered in Bedford, Massachusetts, and operates across two performance locations: North Billerica, Massachusetts (primary manufacturing and distribution) and Bedford, Massachusetts. Progenics competes predominately full-and-open, with no SBA set-aside designations on the majority of its federal contracts, though some delivery orders carry total small business set-aside designations despite the parent schedule having no set-aside. The vendor's primary NAICS category is 325412 (Pharmaceutical Preparation Manufacturing), with a small business size standard of 1,300 employees.

Progenics' capability portfolio centers exclusively on supply of PYLARIFY, a specialized radiopharmaceutical used to detect and localize prostate cancer in PET scans. Recent representative awards include a $9.06 million delivery order from Veterans Integrated Service Network 5 (January 2026, completion January 2031), a $4.77 million delivery order from VISN 12 (May 2025, base plus three option years through April 2026), a $4.64 million delivery order from VISN 22 (November 2024, completion October 2027), and a $3.63 million delivery order from VISN 16 (July 2025, completion June 2029). The company also holds multiple single-award blanket purchase agreements valued at $5.41 million (VISN 10, through September 2030), $9.07 million (VISN 17, through January 2031), and $5.55 million (VISN 21, through December 2027), as well as a $592.78 million Federal Supply Schedule contract awarded April 2025 extending through March 2030. All contracts operate under firm fixed-price terms with no set-aside designation on the parent vehicles.

Customer concentration is heavily weighted toward the Department of Veterans Affairs. The top five customers by award count account for 45% of awards: VISN 10 (29 awards, $31.8 million), VISN 6 (20 awards, $23.7 million), VISN 21 (18 awards, $28.4 million), VISN 12 (16 awards, $610.6 million), and VISN 22 (16 awards, $26.2 million). By potential value, concentration is extreme: VISN 12 alone represents $610.6 million, or 71% of the vendor's combined potential value across all awards ($857.4 million). The Department of Defense Health Agency and the National Institutes of Health Clinical Center represent secondary customers. Of 219 total prime awards tracked in the source data, 185 fall under PSC code for Drugs and Biologicals, with the remainder distributed across medical instruments and laboratory supplies. The vendor has obligated $160.9 million across these awards (19% of combined potential value), indicating substantial backlog available for invoicing.

Activity has fluctuated over the past five years: 50 awards in 2022, 47 in 2023, 34 in 2024, 40 in 2025, and 14 awards year-to-date in 2026 (as of July 2026). Of the 219 total prime awards, 29 carry ultimate completion dates within the next twenty-four months (through July 2027), representing a combined potential value of $51.4 million and therefore significant recompete exposure. Progenics holds no subcontract relationships and does not bid as a subcontractor under other primes—the entire footprint is prime activity. The vendor's federal presence is concentrated on a single product line sold through a single master vehicle (the GSA Pharmaceuticals and Drugs schedule), which creates both dependency and durability: PYLARIFY is the sole source for this diagnostic application, and Progenics is the only authorized manufacturer, making competitive displacement difficult but also creating vulnerability to contract consolidation or alternative procurement strategies by the VA.